| abstract |
The present invention provides compounds defined by Formula 1 or a pharmaceutically acceptable salt thereof, wherein R1, Q, D, V1, m and R2 are as defined herein. The invention also provides pharmaceutical compositions comprising a compound of Formula 1, or a pharmaceutically acceptable salt thereof, as defined herein, together with a pharmaceutically acceptable carrier, diluent or excipient. The invention also provides methods for inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula 1, or a pharmaceutically acceptable salt thereof. The invention also provides methods for treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula 1, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides methods for treating diseases such as heart disease, multiple sclerosis, osteoarthritis and rheumatoid arthritis, arthritis other than osteoarthritis or rheumatoid arthritis, heart failure, inflammatory bowel disease, heart failure, macular degeneration related to e) aging, lung disease Chronic obstructive, asthma, periodontal diseases, psoriasis, atherosclerosis and osteoporosis in a patient, comprising administering to the patient a compound of Formula 1, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition. The invention also provides combinations, which comprise a compound of Formula 1, or a pharmaceutically acceptable salt thereof, together with another pharmaceutically active component, as described herein. |